Treatment Options Section Bibliography

• Bomberg MB, Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve 2004;30:20-37.
• Choudhary PP, Hughes, RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulins. Q J Med. 1995;88:493-507.
• Cocito D, et al. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol. 2002;249:719-722.
• Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases JAMA 2004; 291:2367-2374.
• Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-1497.
• Dalakas MC. Mechanisms of action of IVIG and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59(12Suppl6):S13-S21.
• Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidenced-based indications and safety profile. Pharmacol Ther. 2004;102(3):177-193.
• Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering disease. Intl Immunopharmacol. 2006;6:600-606.
• Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778-783.
• Dyck PJ et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;35:838-845.
• Dyck PJ, O'Brien P, Swanson C, Low P, Daube J, Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985 Aug;35(8):1173-6.
• Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461-465.
• Dyck PJ, Litchy WJ, Kratz KM, et al. a plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838-845.
• Dyck PJ, O'Brien PC, Oviatt KF et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol.1982;11:136-141.
• Faed JM, et al. High dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39:422-425.
• Fialho D. Chan YC, Allen DC, et al. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry. 2006;77(4)544-547.
• Gorson KC, et al. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328.
• Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998;50:84-87.
• Grehl H, et al. Course and effect of high-dose intravenous immunoglobulins in chronic inflammatory neuropathies. In: Joint Meeting on Acquired Polyneuropathies and Motor Neuron Disease, Abstracts, Berlin 1995.
• Hadden RD, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61.
• Hahn AF, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled cross-over study. Brain 1996;119:1067-1077.
• Hahn AF, Bolton CF, Pillay N, et al. Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind, sham-controlled cross-over study. Brain 1996;119:1055-1066.
• Hahn AF, Bolton CF, Zochodne D, Feasby TE. Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP); a double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1078.
• Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Intl Immunopharm. 2006;6:535-542.
• Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose but not with glycine in a patient with immunoglobulin A nephritis. Amer J Kidney Dis. 1996;28:451-453.
• Hughes RAC, Bensa S, Willison HJ, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195-201.
• Hughes RA. Management of chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 2003;63(3):275-287.
• Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferon for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004;18(4):CD003280.
• Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Sys. 2005;10:220-228.
• Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352:1343-1356.
• Korinthenberg R. Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment. Neuropediatrics 1999;30:190-196.
• Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks I, Petteway Jr. SR. Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment. Biologicals 2002;30:153-162.
• Koski, Carol Lee, Initial and Long Term Management of Autoimmune Neuropathies, CNS Drugs, Volume 19, Number 12, 2005 , pp. 1033-1048(16).
• Lemm G. Composition and properties of IVIG preparations that affect tolerability and therapeutic efficacy. Neurology 2002;59:828-832.
• Lindenbau Y, Kissel JT, Mendell JR, Treatment approaches for Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Clin. 2001 Feb;19(1):187-204.
• Mehndiratta MM, Hughes RAC, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). Cochrane Database Syst Rev. 2004;3:CD003906.
• Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449.
• Nemni R, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments. J Neurol Neurosurg Psychiat. 1994;57(Suppl):43-45.
• MMWR. Renal insufficiency and failure associated with immune globulin intravenous therapy. MMWR 1999;48:1985-1998.
• Nimmerjahn and Ravetch. JEM 2007;11.
• Nydegger UW, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Safety 1999;21:171-185.
• Ropper AH. Current treatments for CIDP. Neurology 2003;60(8Suppl3):S16-S22.
• Vallat JM, Hahn AF, Leger JM, et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003; 60(8Suppl3):S23-S28.
• Van der Meche FG, van Doorn PA, Jacobs BC, Inflammatory neuropathies - pathogenesis and the role of intravenous immune globulin, J Clin Immunol. 1995 Nov; 15(6Suppl):63S-69S. Review.
• Van Doorn PA, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy Arch Neurol. 1991;48:217-220.
• Van Doorn PA, et al. On the mechanism of high-dose intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1990;29:57-64.
• Van Doorn PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-212.
• van Furth R, Braat AG, Leijh PC, Gardi A. Opsonic activity and physiochemical characteristics of intravenous immunoglobulin preparations. Vox Sang. 1987;53:70-75.
• Van Schaik IN, Winter JB, de Haaan R, et al. Intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Cochrane Database Syst Rev. 2004;2:CD001797.
• Van Schaik IN, Winer JB, de Haan r, Vermeulen M, Intravenous Immunoglobulin for Chronic Inflammatory Demylinating Polyradiculoneuropathy: a systematic review, Lancet Neurol. 2002 Dec: 1 (8): 491-8 Review.
• Vermeulen M, et al. Plasma and gamma globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci. 1985;70:317-326.
• Vermeulen M, van Doorn PA Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiat. 1993;56:36-39.
• Wilson JR, Bhoopalam H, Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve 1997;20(9):1142-1145.